ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
But late-breaking data raise questions about lack of a dose response.
And first data with a low dose are particularly unimpressive.
Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.
Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.
Initial data on Amgen’s AMG 193 give some Tango investors a headache.